DownloadHi-Res Photo

Aron Flagg, MD

Assistant Professor of Pediatrics (Hematology/Oncology); Outpatient Medical Director , Pediatric Hematology/Oncology/Bone Marrow Transplantation

Research & Publications
Biography
News

Coauthors

Selected Publications

Gimap5-dependent inactivation of GSK3β is required for CD4+ T cell homeostasis and prevention of immune pathologyPatterson AR, Endale M, Lampe K, Aksoylar HI, Flagg A, Woodgett JR, Hildeman D, Jordan MB, Singh H, Kucuk Z, Bleesing J, Hoebe K. Gimap5-dependent inactivation of GSK3β is required for CD4+ T cell homeostasis and prevention of immune pathology. Nature Communications 2018, 9: 430. PMID: 29382851, PMCID: PMC5789891, DOI: 10.1038/s41467-018-02897-7.
Characteristics of Bacteremia in Pediatric Oncology Patients Based on Pathogen Classification as Associated with the Gastrointestinal Mucosa or SkinFlagg A, Worley S, Foster CB. Characteristics of Bacteremia in Pediatric Oncology Patients Based on Pathogen Classification as Associated with the Gastrointestinal Mucosa or Skin. Infection Control And Hospital Epidemiology 2015, 36: 730-733. PMID: 25773335, DOI: 10.1017/ice.2015.48.
Lymphocyte cytosolic protein 1 (L-plastin) I232F mutation impairs granulocytic proliferation and causes neutropeniaMahat U, Garg B, Yang CY, Mehta H, Hanna R, Rogers HJ, Flagg A, Ivanov AI, Corey SJ. Lymphocyte cytosolic protein 1 (L-plastin) I232F mutation impairs granulocytic proliferation and causes neutropenia. Blood Advances 2022, 6: 2581-2594. PMID: 34991157, PMCID: PMC9043934, DOI: 10.1182/bloodadvances.2021006398.
Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.Go RS, Jacobsen E, Baiocchi R, Buhtoiarov I, Butler EB, Campbell PK, Coulter DW, Diamond E, Flagg A, Goodman AM, Goyal G, Gratzinger D, Hendrie PC, Higman M, Hogarty MD, Janku F, Karmali R, Morgan D, Raldow AC, Stefanovic A, Tantravahi SK, Walkovich K, Zhang L, Bergman MA, Darlow SD. Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2021, 19: 1277-1303. PMID: 34781268, DOI: 10.6004/jnccn.2021.0053.
Incidence, Risk Factors, and Outcomes of Patients Who Develop Mucosal Barrier Injury–Laboratory Confirmed Bloodstream Infections in the First 100 Days After Allogeneic Hematopoietic Stem Cell TransplantDandoy CE, Kim S, Chen M, Ahn KW, Ardura MI, Brown V, Chhabra S, Diaz MA, Dvorak C, Farhadfar N, Flagg A, Ganguly S, Hale GA, Hashmi SK, Hematti P, Martino R, Nishihori T, Nusrat R, Olsson RF, Rotz SJ, Sung AD, Perales MA, Lindemans CA, Komanduri KV, Riches ML. Incidence, Risk Factors, and Outcomes of Patients Who Develop Mucosal Barrier Injury–Laboratory Confirmed Bloodstream Infections in the First 100 Days After Allogeneic Hematopoietic Stem Cell Transplant. JAMA Network Open 2020, 3: e1918668. PMID: 31913492, PMCID: PMC6991246, DOI: 10.1001/jamanetworkopen.2019.18668.
Infectious diseases in pediatric transplantation: Literature review 2006–2007Flagg A, Danziger‐Isakov L. Infectious diseases in pediatric transplantation: Literature review 2006–2007. Pediatric Transplantation 2008, 12: 729-736. DOI: 10.1111/j.1399-3046.2008.00985.x.
Extranodal marginal zone B cell lymphoma: An unexpected complication in children with Sjögren's syndromeCollado P, Kelada A, Cámara M, Zeft A, Flagg A. Extranodal marginal zone B cell lymphoma: An unexpected complication in children with Sjögren's syndrome. Reumatología Clínica (English Edition) 2018, 14: 227-229. DOI: 10.1016/j.reumae.2017.01.011.
619 Resolution of Secondary Thrombocytopenia with Thrombopoietin Receptor Agonists in Two Allogeneic Hematopoietic Cell Transplant Recipients Treated at a Pediatric CenterFlagg A, Money L, Bielek K, Majhail N, Kalaycio M, Dean R, Gerds A, Hill B, Liu H, Hamilton B, Jagadeesh D, Sobecks R, Hanna R. 619 Resolution of Secondary Thrombocytopenia with Thrombopoietin Receptor Agonists in Two Allogeneic Hematopoietic Cell Transplant Recipients Treated at a Pediatric Center. Transplantation And Cellular Therapy 2018, 24: s445. DOI: 10.1016/j.bbmt.2017.12.542.
Risk Factors for Infections in Recipients of Hematopoietic Cell Transplantation in Relation to Donor SourceFlagg A, Hanna R, Mossad S, Rybicki L, Hamilton B, Gerds A, Sobecks R, Duong H, Andresen S, Bolwell B, Majhail N, Kalaycio M. Risk Factors for Infections in Recipients of Hematopoietic Cell Transplantation in Relation to Donor Source. Transplantation And Cellular Therapy 2014, 20: s193-s194. DOI: 10.1016/j.bbmt.2013.12.320.
Novel 2009 H1N1 influenza virus infection requiring extracorporeal membrane oxygenation in a pediatric heart transplant recipientFlagg A, Danziger-Isakov L, Foster C, Nasman C, Smedira N, Carl J, Kwon C, Davis S, Boyle G. Novel 2009 H1N1 influenza virus infection requiring extracorporeal membrane oxygenation in a pediatric heart transplant recipient. The Journal Of Heart And Lung Transplantation 2009, 29: 582-584. PMID: 20044274, DOI: 10.1016/j.healun.2009.11.600.
Incidence and risk factors of pain crisis after hematopoietic cell transplantation for sickle cell diseaseKrishnamurti L, Liang J, He Z, Deng Y, Nallagatla V, Hamidi R, Flagg A, Shah N. Incidence and risk factors of pain crisis after hematopoietic cell transplantation for sickle cell disease. Blood Advances 2024, 8: 1908-1919. PMID: 38324722, PMCID: PMC11021890, DOI: 10.1182/bloodadvances.2023010749.
384 Vaso-Occlusive Pain Requiring Hospitalization or Treatment Is Rare Following Successful Hematopoietic Cell Transplantation for Sickle Cell DiseaseKrishnamurti L, He Z, Deng Y, Hamidi R, Flagg A, Shah N. 384 Vaso-Occlusive Pain Requiring Hospitalization or Treatment Is Rare Following Successful Hematopoietic Cell Transplantation for Sickle Cell Disease. Transplantation And Cellular Therapy 2023, 29: s291. DOI: 10.1016/s2666-6367(23)00453-0.
378 Main Reasons for Performing Hematopoietic Cell Transplantation in Patients with Sickle Cell Disease: Evolution over the Last Three DecadesFlagg A, He Z, Deng Y, Hamidi R, Shah N, Krishnamurti L. 378 Main Reasons for Performing Hematopoietic Cell Transplantation in Patients with Sickle Cell Disease: Evolution over the Last Three Decades. Transplantation And Cellular Therapy 2023, 29: s285-s286. DOI: 10.1016/s2666-6367(23)00447-5.
390 Endothelial Complications of Hematopoietic Cell Transplantation for Sickle Cell DiseaseFlagg A, Hamidi R, He Z, Deng Y, Shah N, Krishnamurti L. 390 Endothelial Complications of Hematopoietic Cell Transplantation for Sickle Cell Disease. Transplantation And Cellular Therapy 2023, 29: s296. DOI: 10.1016/s2666-6367(23)00459-1.
379 The Impact of Current Conditioning Regimen, T Cell Depletion and Graft Versus Host Disease Prophylaxis on the Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Sickle Cell DiseaseShah N, Flagg A, Hamidi R, Hugo H, Deng Y, Krishnamurti L. 379 The Impact of Current Conditioning Regimen, T Cell Depletion and Graft Versus Host Disease Prophylaxis on the Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Sickle Cell Disease. Transplantation And Cellular Therapy 2023, 29: s286-s287. DOI: 10.1016/s2666-6367(23)00448-7.
392 Avascular Necrosis Following Hematopoietic Cell Transplantation for Sickle Cell DiseaseHamidi R, He Z, Deng Y, Flagg A, Shah N, Krishnamurti L. 392 Avascular Necrosis Following Hematopoietic Cell Transplantation for Sickle Cell Disease. Transplantation And Cellular Therapy 2023, 29: s297-s298. DOI: 10.1016/s2666-6367(23)00461-x.
Endothelial Complications of Hematopoietic Cell Transplantation for Sickle Cell DiseaseFlagg A, Hamidi R, Deng Y, Shah N, Krishnamurti L, He Z. Endothelial Complications of Hematopoietic Cell Transplantation for Sickle Cell Disease. Blood 2022, 140: 10460-10461. DOI: 10.1182/blood-2022-169107.
434 Adolescent and Young Adult Patients’ Experiences with Hematopoietic Stem Cell Transplant in a Pediatric Hospital EnvironmentBoyd K, Agli J, Bowers A, Flagg A, Shah N. 434 Adolescent and Young Adult Patients’ Experiences with Hematopoietic Stem Cell Transplant in a Pediatric Hospital Environment. Transplantation And Cellular Therapy 2022, 28: s336-s337. DOI: 10.1016/s2666-6367(22)00594-2.
Lymphocyte Cytosolic Protein 1 I232F Mutation Impairs Granulocytic Proliferation with a G2/M Block in Severe NeutropeniaMahat U, Garg B, Mehta H, Rogers H, Ivanov A, Yang C, Flagg A, Corey S. Lymphocyte Cytosolic Protein 1 I232F Mutation Impairs Granulocytic Proliferation with a G2/M Block in Severe Neutropenia. Blood 2021, 138: 434. DOI: 10.1182/blood-2021-152781.
Classical Hodgkin Lymphoma of cystic thymus in a patient with infectious mononucleosis: Diagnostic challenges and practical considerationsBhunia N, Ondrejka S, Flagg A, Buhtoiarov I. Classical Hodgkin Lymphoma of cystic thymus in a patient with infectious mononucleosis: Diagnostic challenges and practical considerations. Pediatric Hematology Oncology Journal 2021, 6: 81-83. DOI: 10.1016/j.phoj.2021.03.002.
Brachial plexus chloroma as a presenting feature of relapse in a child with KMT2A-rearranged acute lymphoblastic leukemia, a case reportPruitt J, Flagg A, Hanna R, Rotz SJ. Brachial plexus chloroma as a presenting feature of relapse in a child with KMT2A-rearranged acute lymphoblastic leukemia, a case report. Pediatric Hematology And Oncology 2020, 38: 179-183. PMID: 33150840, PMCID: PMC7987733, DOI: 10.1080/08880018.2020.1826071.
Severe megaloblastic anemia: Vitamin deficiency and other causesSocha DS, DeSouza SI, Flagg A, Sekeres M, Rogers HJ. Severe megaloblastic anemia: Vitamin deficiency and other causes. Cleveland Clinic Journal Of Medicine 2020, 87: 153-164. PMID: 32127439, DOI: 10.3949/ccjm.87a.19072.
Ovarian Torsion in an Adolescent with Beckwith-Wiedemann Syndrome and Unilateral Tubo-ovarian HyperplasiaMahat U, Dermawan JKT, Herman R, Mamoun I, Flagg A. Ovarian Torsion in an Adolescent with Beckwith-Wiedemann Syndrome and Unilateral Tubo-ovarian Hyperplasia. Journal Of Pediatric And Adolescent Gynecology 2019, 32: 446-449. PMID: 30981832, DOI: 10.1016/j.jpag.2019.04.008.
Letermovir for Secondary Cytomegalovirus (CMV) Prophylaxis in a Pediatric Stem Cell Transplant PatientLe J, Zembillas A, Stanton M, Dahl E, Hanna R, Flagg A, Rivard K, Gonzalez B. Letermovir for Secondary Cytomegalovirus (CMV) Prophylaxis in a Pediatric Stem Cell Transplant Patient. Transplantation And Cellular Therapy 2019, 25: s282-s283. DOI: 10.1016/j.bbmt.2018.12.354.
Time to Transplantation (TTT) for Acute Myeloid Leukemia (AML) in First Complete Remission (CR1) Is Comparable Among Adolescent and Young Adults (AYAs) and Older AdultsMathanda R, Hamilton B, Rybicki L, Advani A, Bolwell B, Flagg A, Hanna R, Kalaycio M, Sobecks R, Majhail N, Rotz S. Time to Transplantation (TTT) for Acute Myeloid Leukemia (AML) in First Complete Remission (CR1) Is Comparable Among Adolescent and Young Adults (AYAs) and Older Adults. Transplantation And Cellular Therapy 2019, 25: s126. DOI: 10.1016/j.bbmt.2018.12.409.
Adolescent and Young Adult (AYA) Hematopoietic Cell Transplantation (HCT) Recipients Have Similar Quality of Life (QoL) Compared to Older Adults in the First Year Post-TransplantationMathanda R, Hamilton B, Rybicki L, Advani A, Bolwell B, Colver A, Dabney J, Ferraro C, Flagg A, Hanna R, Kalaycio M, Lawrence C, McLellan L, Sobecks R, Majhail N. Adolescent and Young Adult (AYA) Hematopoietic Cell Transplantation (HCT) Recipients Have Similar Quality of Life (QoL) Compared to Older Adults in the First Year Post-Transplantation. Blood 2018, 132: 4768. DOI: 10.1182/blood-2018-99-113027.
Sporadic Burkitt Lymphoma with Orbital Extramedullary InfiltrationArepalli S, Flagg A, Venkat A, Singh AD. Sporadic Burkitt Lymphoma with Orbital Extramedullary Infiltration. Ocular Oncology And Pathology 2018, 5: 46-49. PMID: 30675476, PMCID: PMC6341329, DOI: 10.1159/000488710.
Gimap5-dependent inactivation of GSK3β is required for CD4+ T cell homeostasis and prevention of immune pathologyPatterson A, Endale M, Lampe K, Flagg A, Woodgett J, Bleesing J, Hoebe K. Gimap5-dependent inactivation of GSK3β is required for CD4+ T cell homeostasis and prevention of immune pathology. The Journal Of Immunology 2018, 200: 116.3-116.3. DOI: 10.4049/jimmunol.200.supp.116.3.
563 Safety of Allogeneic HCT in Beta Thalassemia Patients with Chronic Hepatitis C Virus Infections Treated at a Pediatric CenterRamgopal A, Hanna R, Flagg A, Buhtoiarov I, Majhail N, Dean R, Hamilton B, Gerds A, Money L, Bielek K. 563 Safety of Allogeneic HCT in Beta Thalassemia Patients with Chronic Hepatitis C Virus Infections Treated at a Pediatric Center. Transplantation And Cellular Therapy 2018, 24: s387. DOI: 10.1016/j.bbmt.2017.12.479.
514 Impact of MHC Class I Chain-Related Gene a (MICA) Mismatch on Haploidentical Hematopoietic Cell Transplantation OutcomesPatel S, Rybicki L, Yurch M, Thomas D, Jagadeesh D, Dean R, Liu H, Flagg A, Gerds A, Hill B, Hanna R, Hamilton B, Pohlman B, Kalaycio M, Bolwell B, Zhang A, Majhail N, Askar M, Sobecks R. 514 Impact of MHC Class I Chain-Related Gene a (MICA) Mismatch on Haploidentical Hematopoietic Cell Transplantation Outcomes. Transplantation And Cellular Therapy 2018, 24: s418-s419. DOI: 10.1016/j.bbmt.2017.12.428.
200 Impact of MHC Class I Chain-Related Gene a (MICA) Mismatch on Umbilical Cord Blood Hematopoietic Cell TransplantationPatel S, Rybicki L, Yurch M, Thomas D, Jagadeesh D, Dean R, Liu H, Flagg A, Cober E, Mossad S, Gerds A, Hill B, Hanna R, Hamilton B, Pohlman B, Kalaycio M, Bolwell B, Zhang A, Majhail N, Askar M, Sobecks R. 200 Impact of MHC Class I Chain-Related Gene a (MICA) Mismatch on Umbilical Cord Blood Hematopoietic Cell Transplantation. Transplantation And Cellular Therapy 2018, 24: s190. DOI: 10.1016/j.bbmt.2017.12.300.
356 Propensity Matched Analysis of Autologous Hematopoietic Stem Cell Transplantation Outcomes in Solid Organ Transplant RecipientsPatel S, Rybicki L, Corrigan D, Jagadeesh D, Dean R, Liu H, Flagg A, Gerds A, Hill B, Hanna R, Bolwell B, Pohlman B, Kalaycio M, Sobecks R, Majhail N, Hamilton B. 356 Propensity Matched Analysis of Autologous Hematopoietic Stem Cell Transplantation Outcomes in Solid Organ Transplant Recipients. Transplantation And Cellular Therapy 2018, 24: s285. DOI: 10.1016/j.bbmt.2017.12.255.
Mycobacterium genavense‐induced spindle cell pseudotumor in a pediatric hematopoietic stem cell transplant recipient: Case report and review of the literatureCoelho R, Hanna R, Flagg A, Stempak LM, Ondrejka S, Procop GW, Harrington S, Zembillas A, Kusick K, Gonzalez BE. Mycobacterium genavense‐induced spindle cell pseudotumor in a pediatric hematopoietic stem cell transplant recipient: Case report and review of the literature. Transplant Infectious Disease 2017, 19 PMID: 28039955, DOI: 10.1111/tid.12656.
Evaluation of Ciprofloxacin in the Treatment of BK VIRUS-Associated Hemorrhagic Cystitis in Hematopoietic CELL Transplant RecipientsArango M, Weber C, Neuner E, Cober E, Kalaycio M, Jagadeesh D, Pohlman B, Dean R, Andresen S, Gerds A, Hanna R, Abounader D, Flagg A, Bolwell B, Majhail N, Liu H. Evaluation of Ciprofloxacin in the Treatment of BK VIRUS-Associated Hemorrhagic Cystitis in Hematopoietic CELL Transplant Recipients. Transplantation And Cellular Therapy 2016, 22: s169-s170. DOI: 10.1016/j.bbmt.2015.11.533.
Incidence and Risk Factors for Central Nervous System Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute LeukemiaDhir A, Hanna R, Rybicki L, Abounader D, Flagg A, Hamilton B, Hill B, Jagadeesh D, Liu H, Gerds A, Kalaycio M, Bolwell B, Majhail N. Incidence and Risk Factors for Central Nervous System Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia. Transplantation And Cellular Therapy 2016, 22: s201-s202. DOI: 10.1016/j.bbmt.2015.11.592.
10-Year Outcomes after Allogeneic Hematopoietic Cell Transplantation (HCT) in Adolescent and Young Adults (AYA)Hanna R, Rybicki L, Abounader D, Bolwell B, Dean R, Duong H, Flagg A, Gerds A, Hamilton B, Hill B, Kalaycio M, Sobecks R, Majhail N. 10-Year Outcomes after Allogeneic Hematopoietic Cell Transplantation (HCT) in Adolescent and Young Adults (AYA). Blood 2014, 124: 1183. DOI: 10.1182/blood.v124.21.1183.1183.
Testicular Myeloid Sarcoma: A Rare Manifestation of Acute Myeloid Leukemia in an InfantTran CN, Collie AM, Flagg A, Rhee A. Testicular Myeloid Sarcoma: A Rare Manifestation of Acute Myeloid Leukemia in an Infant. Urology 2014, 84: 925-927. PMID: 25260454, DOI: 10.1016/j.urology.2014.07.005.
Transient abnormal myelopoiesis of a newborn not associated with chromosome 21 abnormalities or GATA1 mutationsNakashima MO, Shetty S, Chicka M, Flagg A, Eng C, Cotta CV. Transient abnormal myelopoiesis of a newborn not associated with chromosome 21 abnormalities or GATA1 mutations. Pediatric Blood & Cancer 2014, 62: 353-355. PMID: 25175265, DOI: 10.1002/pbc.25226.
Synchronous occurrence of nasopharyngeal carcinoma and Hodgkin lymphomaStokken J, Manz RM, Flagg A, Gowans L, Anne S. Synchronous occurrence of nasopharyngeal carcinoma and Hodgkin lymphoma. International Journal Of Pediatric Otorhinolaryngology 2013, 78: 154-156. PMID: 24290306, DOI: 10.1016/j.ijporl.2013.10.055.
587 Long-Term Outcomes in Pediatric Heart Transplant Recipients Treated for Neoplasia: A Single-Institution ExperienceMarcotty A, Flagg A, Nasman C, Brubaker J, Boyle G. 587 Long-Term Outcomes in Pediatric Heart Transplant Recipients Treated for Neoplasia: A Single-Institution Experience. The Journal Of Heart And Lung Transplantation 2011, 30: s197. DOI: 10.1016/j.healun.2011.01.599.
Angular velocity: a new method to improve prediction of ventricular fibrillation durationSherman LD, Flagg A, Callaway CW, Menegazzi JJ, Hsieh M. Angular velocity: a new method to improve prediction of ventricular fibrillation duration. Resuscitation 2004, 60: 79-90. PMID: 15002486, DOI: 10.1016/j.resuscitation.2003.07.001.

Clinical Trials

Conditions	Study Title
Brain and Nervous System; Pediatrics	A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
Brain and Nervous System	A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
Other Hematopoietic; Pediatrics	A Phase I/II Trial of Reduced Intensity Conditioning and Familial HLA-Mismatched Bone Marrow Transplantation in Children With Non-Malignant Disorders
Unknown Sites	PrOspective Non-interventional Study in Patients With Locally Advanced or Metastatic TRK Fusion Cancer Treated With Larotrectinib
Other Hematopoietic; Supportive Care	Early HLA Matched Sibling Hematopoietic Stem Cell Transplantation for Children With Sickle Cell Disease: A Sickle Transplant Alliance for Research (STAR) Trial
Brain and Nervous System; Pediatrics	A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)
Leukemia, not otherwise specified; Leukemia, other; Pediatrics	A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Leukemia, other; Pediatrics	A Phase 3 Trial Investigating Blinatumomab ( NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
Bones and Joints; Kidney; Pediatrics; Soft Tissue	Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumors
Other Hematopoietic; Pediatrics; Sickle Cell Disorders	A Study of Hematopoietic Stem Cell Transplantation (HSCT) in Non-Malignant Disease Using a Reduced-Intensity Preparatory Regime
Bones and Joints; Brain and Nervous System; Leukemia, not otherwise specified; Leukemia, other; Lymphoid Leukemia	NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Unknown Sites	Neuropsychological and Behavioral Testing in Younger Patients With Cancer
Pediatrics	A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy With Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) Plus VINO-CPO Maintenance in Patients With High Risk Rhabdomyosarcoma (HR-RMS)
Sickle Cell Disorders	A Phase 1/2 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous Clustered Regularly Interspaced Short Palindromic Repeats Gene-edited CD34+ Human Hematopoietic Stem and Progenitor Cells (EDIT-301) in Subjects With Severe Sickle Cell Disease
Pediatrics	A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma (RELATIVITY-069)
Pediatrics	A Phase 3 Study of Selumetinib (NSC# 748727) or Selumetinib in Combination With Vinblastine for Non-NF1, Non-TSC Patients With Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations

Edit Profile

Aron Flagg, MD

Contact Information

Patient Care

Research & Publications

Biography

News

Coauthors

Selected Publications

Clinical Trials